Tag: GLP-1 market

Global Companies

Eli Lilly Bets $6 Billion on Alabama Plant for Obesity Drugs

Eli Lilly just dropped $6 billion on a massive new plant in Alabama — and the main reason is one...

09/12/2025

5 views

Read More

Global Companies

Pfizer Bets Big on Oral Obesity Pill in $2.1B China Deal

Pfizer just dropped $150M upfront (and up to $2.1B total) on a Chinese company's oral obesity pill. After losing the...

09/12/2025

3 views

Read More

Global Markets

Weight Loss Drugs Future: Pills, Rivals, Insurance

The weight loss drug arena is exploding toward a $100 billion future, with pills on the horizon and rivals closing...

02/11/2025

5 views

Read More

Market News

Pfizer’s Big Bet on Obesity Drugs: Why Stocks Soared

Pfizer’s $7B move to dominate obesity drugs sent its stock soaring. But what makes this deal a game-changer for investors?...

22/09/2025

3 views

Read More

Market News

Why Lilly’s Obesity Pill Miss Shook Investors

Lilly's stock crashed after its obesity pill trial fell short. What went wrong, and what’s next for the weight-loss drug...

07/08/2025

5 views

Read More

Market News

Compounded GLP-1s: Impact On Health And Markets

Over a million Americans use unapproved GLP-1 drugs, shaking up markets and health. What’s next for investors and patients? Click...

31/07/2025

2 views

Read More

Stocks

Eli Lilly’s Obesity Pill: Stock Surge Insights

Eli Lilly's new obesity pill sent shares soaring. Can it dominate the weight-loss market, or will rivals catch up? Click...

17/04/2025

0 views

Read More

Global Companies

Eli Lilly’s Weight Loss Pill: A Game-Changer?

Eli Lilly's new weight loss pill shows promise in trials, but can it dominate the market? Dive into the results...

17/04/2025

0 views

Read More

Smart Money

Pfizer Halts Weight Loss Pill: What’s Next?

Pfizer’s weight loss pill was scrapped after a liver scare. What does this mean for obesity drugs and biotech stocks?...

14/04/2025

0 views

Read More